Fusion Antibodies (FAB)

Company name:Fusion Antibodies Plc
EPIC:FABTrading Currency:GBX
Market Sector:AMQ1ISIN:GB00BDQZGK16
Market Segment:ASQ1Share Type:DE
WWW Address:http://www.fusionantibodies.com/Description:ORD 4P
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Offer Open High Low Volume
 78.50 images.advfn.com/imagesnew/2/gb/dot 0.0 [0.00] 75.00 82.00 78.50 78.50 78.50 -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 17.34 22.09 0.10 -5.70 - - - 86.00 - 24.50

Fusion Antibodies Key Figures

(at previous day's close)
Market Cap.17.34m
Shares In Issue22.09m
Prev. Close78.50
PE Ratio- 
Dividend Yield-%
EPS - basic-5.70p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-4.97p
Return On Equity (ROE)-23.62%
Operating Margin-68.74%
PEG Factor- 
EPS Growth Rate-32.56%
Dividends PS Growth Rate-%
Net Debt-1.10m
Gross Gearing14.23%
Quick Assets4.41m
Net Working Capital3.85m
Intangibles / Fixed Assets0.39%
Turnover PS9.88p
Pre-Tax Profit PS-6.79p
Retained Profit PS-5.72p
Cash PS8.98p
Net Cash PS5.38p
Net Tangible Asset Value PS *24.21p
Net Asset Value PS24.24p
Spread7.00 (8.54%) 

Fusion Antibodies Balance Sheet

FAB:Liabilities+EQFAB:Assets

Share Price Performance

Sample Period HighLow
1 week80.5075.00
4 weeks80.5068.50
12 weeks80.5064.50
1 year86.0024.50

Share Price Chart (5 years)

Fusion Antibodies Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week75.003.504.6775.000.0177.73
4 weeks70.508.0011.3568.500.0174.70
12 weeks66.0012.5018.9464.500.0172.88
26 weeks57.5021.0036.5253.500.0167.21
1 year52.5026.0049.5224.500.0153.96
3 years83.50-5.00-5.9924.500.01109.93
5 years83.50-5.00-5.9924.500.01109.93

Fusion Antibodies Key Management Ratios

Fusion Antibodies Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 2.58 
Tobin's Q Ratio (excl. intangibles)2.58 
Dividend Yield-%
Market-to-Book Ratio3.24 
Price-to-Pre-Tax Profit PS-11.56 
Price-to-Retained Profit PS-13.72 
Price-to-Cash Flow PS-15.79 
Price-to-Sales PS7.95 
Price-to-Net Tangible Asset Value PS3.24 
Price-to-Cash PS8.74 
Net Working Capital PS17.44 
Price Pct to Working Capital PS4.50%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Fusion Antibodies Financial Ratios

(Leverage Ratios)
Debt Ratio1.70%
Debt-to-Equity Ratio0.02 
Debt-to-Equity Ratio (excl. Intgbl)0.02 
Debt-to-Equity Market Value0.01 
Net Gearing-17.55%
Net Gearing (excl. Intangibles)-17.57%
Gross Gearing14.23%
Gross Gearing (excl. Intangibles)14.25%
Gearing Under 1 Year12.75%
Gearing Under 1 Year (excl. Intgbl)12.76%
Assets/Equity1.17 
Cash/Equity37.06 
(Liquidity Ratios)
Net Working Capital to Total Assets61.71%
Current Ratio5.84 
Quick Ratio (Acid Test)5.54 
Liquidity Ratio2.49 
Cash & Equiv/Current Assets42.69%
(Solvency Ratios)
Enterprise Value15.45m
CFO/Sales-0.50 
CFO/Attributable Profit- 
CFO/Assets-0.18 
CFO/Debt-1.24 
Total Debt/Equity Market Value0.05 
Total Debt/Sales0.41 
Total Debt/Pre-Tax Profit-0.59 
Total Debt0.89m
Total Debt/Net Current Assets0.23%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs1 
Beta (60-Mnth)Beta (36-Mnth)
0.10120.1686

Fusion Antibodies Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-27.54%
Return On Assets (ROA)-18.80%
Net Profit Margin-57.95%
Assets Turnover0.32 
Return On Equity (ROE)-23.62%
Return On Investment (ROI)-20.92%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-57.95%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.37 
Fixed Assets Turnover2.04 
Current Assets Turnover0.39 
Net Working Capital Turnover 
Inventory Turnover13.45 
(Other Operating Ratios)
Total Assets-to-Sales3.08 
Debtors-to-Sales103.37%
Debt Collection Period377.29Days

Fusion Antibodies Dividends

Sorry No Data Available

Fusion Antibodies Fundamentals

 31 Mar 2018 (GBP)31 Mar 2019 (GBP)
turnover2.69100.00%2.18100.00%m
pre tax profit-0.71-26.44%-1.50-68.74%m
attributable profit-0.70-26.01%-1.26-57.95%m
retained profit-0.70-26.01%-1.26-57.95%m
eps - basic (p)-4.30 -5.70 
eps - diluted (p)-4.30 -5.70 
dividends per share- - 

Fusion Antibodies Balance Sheet

 31 Mar 2018 (GBP)31 Mar 2019 (GBP)
FAB:Liabilities+EQFAB:AssetsFAB:Liabilities+EQFAB:Assets
 31 Mar 2018 (GBP)31 Mar 2019 (GBP)
ASSETS
fixed assets fixed assets0.557.58%1.5925.44%m
intangibles intangibles--%0.010.10%m
fixed investments fixed investments--%--%m
current assets - other current assets - other--%--%m
stocks stocks0.081.13%0.243.89%m
debtors debtors2.0928.98%2.4238.79%m
cash & securities cash & securities4.4962.30%1.9831.79%m
TOTAL7.21100%6.24100%m
LIABILITIES
creditors - short creditors - short0.577.91%0.8012.75%m
creditors - long creditors - long0.060.88%0.091.48%m
creditors - other creditors - other--%--%m
subordinated loans subordinated loans--%--%m
insurance funds insurance funds--%--%m
TOTAL0.638.79%0.8914.23%m
EQUITY
ord cap, reserves ord cap, reserves6.5891.21%5.3585.77%m
prefs, minorities prefs, minorities--%--%m
TOTAL6.5891.21%5.3585.77%m
OTHER
NAV Basic- - 
NAV Diluted- - 

Fusion Antibodies Cash Flow Statement

31 Mar 2018 (GBP)31 Mar 2019 (GBP)
Operating CF0.08-1.10m
Pre-Financing CF-0.37-2.48m
Retained CF4.21-2.51m

Fusion Antibodies Brokers

NameActivityTypeMnemonicCode
Fairfax I.S. PLCMarket Maker(MMF)Broker/DealerFFAXFRFXGB21001
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC
Your Recent History
LSE
FAB
Fusion Ant..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191206 11:42:18